AIIMS director Dr Randeep Guleria has said that Hyderabad based Bharat Biotech’s anti-Covid-19 shot, Covaxin is likely to be approved for children by September.
Dr Guleria told India Today that the trial data would be made available by September and the vaccine itself is likely to be approved in the same month.
He further added that the Pfizer-BioNTech shot, if approved in India, could be another alternative for children to be vaccinated with.
As several experts have projected that a potential third wave will be particularly hard-hitting on children, Covaxin’s trial on children, aged between 2 and 17, is being conducted at AIIMS Delhi and Patna